A compounding business continues to compound problems for AmerisourceBergen (ABC), one of the nation’s largest pharmaceutical wholesalers.

The company disclosed that it remains unclear when its Pharmedium Services unit would resume shipments from a key facility in Memphis, thanks to an ongoing review by the Food and Drug Administration, according to a new regulatory filing. This is a major reversal from an upbeat forecast delivered just two months ago, when AmerisourceBergen indicated distribution would get under way before the end of September.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy